Grufity logo
Grufity logo
ADXS

ADXS - Advaxis Inc Stock Price, Fair Value and News

$0.600.00 (0.00%)
Market Closed as of 04 Feb 2026, 04:00 pm ET

Price Targets

ADXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADXS Price Action

Last 7 days

11.8%

Last 30 days

1325%

Last 90 days

1040%

Trailing 12 Months

1800%

ADXS RSI Chart

ADXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADXS Valuation

Market Cap

7.1M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

547.26

EV/EBITDA

-0.2

Price/Free Cashflow

-0.24

ADXS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ADXS Fundamentals

ADXS Revenue

ADXS Earnings

ADXS Profitability

Free Cashflow Yield

-415.41%

ADXS Investor Care

Revenue & Growth

How Advaxis Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2023465.7K239.3K-13.0K
20222.6M1.4M-250.0K
20211.2M2.2M-3.2M
2020-14.0M7.1M253.0K
201923.7M23.1M22.0M20.9M
201810.3M8.6M6.7M6.1M
2017---12.0M
2016----
2010--269.1K508.5K
2009---29.7K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Advaxis Inc

ADXS
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.
0
 CEO
 WEBSITEayalapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Advaxis Inc Frequently Asked Questions

ADXS is the stock ticker symbol of Advaxis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Feb 04 2026, market cap of Advaxis Inc is 7.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Feb 04 2026, ADXS's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 547.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADXS PE ratio will change depending on the future growth rate expectations of investors.